The examination, entitled “Multicenter Assessment of Survivors of Kidney Disease After COVID-19 (MASKeD-COVID)”, is conducted in the Pred-MAKER exam announced last April 20, 2020, which focuses on the effect on COVID-19 in acute inpatients (https://renalytixai.com/kidneyintelx-covid-19/). Research groups expected to participate in the exam come with the Mount Sinai Icahn School of Medicine Health System in Mount Sinai in New York, Yale New Haven Health/Yale School of Medicine, Michigan Medicine/University of Michigan Medical School, Johns Hopkins Medicine/La Johns Hopkins Medical University School, and Rutgers, New Jersey State University/Rutgers New Jersey Medical School.
“With the pandemic spread of COVID-19 and the accumulation of morbidity and mortality due to COVID-19 in patients with diabetes, IRC and acute kidney damage, it is imperative to describe the underlying mechanisms of COVID-associated renal impairment and expand responses to advise the patient in charge,” said F. Perry Wilson, MD, lead researcher at MSCECArray MASKeD-COVID, Yale Of School of Medicine. “The way to achieve this is collaboration in all aspects, adding knowledge sharing, biomarker research, knowledge research and clinical translation. RenalytixAI and Mount Sinai have assembled an exceptional team to address critical problems similar to COVID-19 and kidney disease.”
“This collaboration technique is to expand some vital discoveries from the respective teams to date,” said Matthias Kretzler, M.D., a senior researcher at MASKeD-COVID at the University of Michigan. “We have shown that ACE2 (the SARS-CoV-2 receptor) is coexpressed with a set of genes in the proximal tubules that also have purposes in viral input, viral replication, and innate immunity. 2 We take a look at the future with this exceptional team for additional studies and additional outline of the underlying mechanisms of COVID-associated kidney disease.
SARS-CoV-2 is the idea of causing acute kidney damage through multiple mechanisms, adding severe inflammation, endothelial lesions, microtrombians and, in all likelihood, direct invasion of the virus in renal epithelial cells.3 The burden and occurrence of post-COVID-19 RC and end-stage renal failure (ESKD) is recently unknown, given the recent onset of the pandemic. However, new evidence suggests that patients who COVID-19 will revel in a greater threat of kidney disease, adding:
“There are still many questions to answer about COVID-19 and kidney disease. For example, we do not yet know the threat and mediators of the transition from AKI to CKD after COVID-19. We also do not know the long-term predictors long-term results after COVID-19,” said Evren Azeloglu, Ph.D., assistant professor of nephrology and pharmacological sciences at Mount Sinai’s Icahn School of Medicine. “In addition, we want to perceive how this ‘second success’ of COVID-19 interacts with other threats such as the underlying APOL1 genotypes to build the possibility of protein-like nephropathy. More paints on biomarker research, histopathology of renal tissues and gene expression signatures are expected to perceive the disease and its long-term implications.
About The Mount Sinai Health System The Mount Sinai Health System is New York City’s largest college medical formula, spanning 8 hospitals, a leading medical school, and a vast network of outpatient practices throughout the New York metropolitan area. Mount Sinai is a national and foreign source of unprecedented translational education, studies and discoveries, and collaborative clinical leadership to ensure we provide the highest quality of care, from prevention to the remedy of serious and complex human diseases. The fitness care formula includes more than 7,200 physicians and has a network of physically powerful and ever-expanding multi-specialized services, adding more than 400 outpatient practice locations in the five counties of New York, Westchester and Long Island. Mount Sinai Hospital ranks 14th in the “Table of Honor” of the 20 most sensitive hospitals in the country and the Icahn School of Medicine among the 20 most sensitive medical schools in the country. Mount Sinai Health System hospitals are regionally classified by specialty and our physicians rank as the 1% maximum sensitive of all physicians nationwide through U.S.News – World Report.
For more information, https://www.mountsinai.org or search for Mount Sinai on Facebook, Twitter, and YouTube.
About RenalytixAIRenalytixAI is a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management in CKD to help drive improved patient outcomes and significantly lower healthcare costs. KidneyIntelX, our first-in-class diagnostic platform, employs a proprietary artificial intelligence-enabled algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and extensive personalized patient data from electronic health record, or EHR, systems to generate a unique patient risk score. KidneyIntelX is based on technology developed by Mount Sinai faculty and licensed to RenalytixAI. Mount Sinai and Mount Sinai faculty have a financial interest in RenalytixAI.
Notes: 1 https://covidtracking.com/data/download2 https://www.medrxiv.org/content/10.1101/2020.05.09.20096511v13, https://www.nephjc.com/news/covidaki5 https: // www.medrxiv.org/content/10.1101/2020.05.0.200909v16 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788581/7 https://jasn.asnjournals.org/content/31/ 7 / 13808 https://www.fiercehealthcare.com/hospitals-health-systems/mount-sinai-launches-post-covid-care-center-for-ongoing-treatments
This press release includes forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not old facts and, in some cases, would possibly be known through terms such as “possibly,” “want,” “you can just,” “expect,” “plan,” “anticipate, and “believe.” These statements include, but are not limited to, statements regarding the conduct, design and timing of the MASKeD-COVID clinical trial, adding the timing of the effects of the initial studies and the timing and feasibility of marketing KidneyIntelX in the COVID-19 population, as well as the participation of other establishments in the MASKeD-COVID clinical trial and the prospective benefits of KidneyIntelX in the assessment of kidney disease in the context of COVID-19. Forward-looking statements are based on existing management reviews and assumptions and involve hazards and uncertainties that may also cause actual effects, functionality, or occasions to differ materially from those expressed or implied in such statements. We may not achieve the plans and objectives disclosed in the forward-looking statements, and you deserve not to rely too much on our forward-looking statements. A variety of vital points may also cause actual effects or occasions to differ materially from those that may be expressed or implied through our forward-looking statements, adding those described in the “Risk Factors” segment of our final prospectus submitted to the Securities and Exchange Commission (SEC) on July 17, 2020 and other submissions we make from time to time with the SEC. All data contained in this press release are as of the date of the press release, and we assume no legal responsibility to publicly update any forward-looking statements, whether as a result of new data, long-term occasions or otherwise, unless required by law.
US Media Contact: Jennifer MoritzZer 0 to 5ive for RenalytixAI (917) [email protected]